Opendata, web and dolomites


Kidney Injury Technology

Total Cost €


EC-Contrib. €






 KIT project word cloud

Explore the words cloud of the KIT project. It provides you a very rough idea of what is the project "KIT" about.

clinical    reference    worldwide    royalties    validation    upfront    10    critical    commercialization    marker    population    rate    biomarker    transfer    elevated    penetration    2017    deadly    sales    69    human    dismally    incident    handling    market    health    license    smes    2023    price    sought    manufacturing    billion       poses    diagnostics    capacity    acquire    grows    yield       annual    128    elisa    prototype    clinically    laid    international       tests    renal    patient    regulated    thorough    prognosis    sale    sme    2018    maturity    vitro    thereafter    unitary    inren    aki    company    income    envisioned    yearly    revolutionary    channels    people    consolidation    reduce    economic    technological    instrument    samples    35    posing    gt    disease    acute    expenditure    standard    bio    diagnostic    ivd    initially    patented    huge    companies    gold    transferability    650    incidence    started    competitors       global    kit   

Project "KIT" data sheet

The following table provides information about the project.


Organization address
postcode: 37007
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2014
 Funding Scheme SME-1
 Starting year 2014
 Duration (year-month-day) from 2014-11-01   to  2015-04-30


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    BIO-INREN SL ES (SALAMANCA) coordinator 50˙000.00


 Project objective

Bio-inRen has developed and patented a revolutionary biomarker-based diagnostic system for a highly and increasingly incident (>10% yearly) and dismally deadly disease (Acute Renal Failure -AKI) posing a huge global health and economic problem worldwide. Bio-inRen’s diagnostic system is envisioned to 1) change the concept and approach to AKI clinical handling, 2) become a reference diagnostic, 3) reduce AKI incidence (by 2.5-5% initially) and improve patient prognosis, and 4) reduce the elevated cost associated to AKI (1% of their global health expenditure, which will be reduced initially in 650 M € in this 1.35 billion people population). An ELISA-based, clinically useful prototype kit has been developed for measurement of human samples. Clinical validation has started, although Bio-inRen’s system needs thorough clinical validation to acquire technological maturity and transferability, for which Phase I and II SME instrument are necessary, on which all the company’s resources will be laid. As a new concept, Bio-inRen’s technology has no competitors in the market or under development. The In Vitro Diagnostic Market grows at a 7% annual rate and will reach $69.1 billion by 2017. AKI-specific market is estimated at 3.5 M cases and 70 M diagnostic tests of the existing gold standard marker. Because Diagnostics is a global and regulated market, Bio-inRen will license the system to large companies and SMEs in the IVD market with manufacturing capacity and international commercialization channels. Technology transfer is expected by 2018 to yield 1 M € upfront and 5% royalties on sales thereafter. 5% market penetration is sought by 2023. As of today, 5% of 70 M tests poses 3.5 M tests as Bio-inRen’s market (6.4 M tests by 2023 at 7% annual growth rate). At a unitary sale price of 20 €/test, this means 128 M €. 5% royalties will produce a yearly income of 6.4 M € to Bio-inRen, which are critical for the consolidation and growth of the company.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "KIT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "KIT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More